Geneos Wealth Management Inc. Buys 1,337 Shares of Stryker Corporation $SYK

Key Points

• Geneos Wealth Management Inc. increased its holdings in Stryker Corporation by 9.5%, acquiring an additional 1,337 shares during the 1st quarter, bringing their total to 15,355 shares valued at $5,716,000.
• Analysts have set price targets for Stryker ranging from $415.00 to $455.00, with a consensus average price target of $431.42 and a majority rating it as a "Moderate Buy."
• Stryker is set to pay a quarterly dividend of $0.84 per share on October 31st, which translates to an annualized dividend of $3.36 and a yield of 0.9%.

Geneos Wealth Management Inc. increased its stake in Stryker Corporation (NYSE:SYK - Free Report) by 9.5% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,355 shares of the medical technology company's stock after acquiring an additional 1,337 shares during the quarter. Geneos Wealth Management Inc.'s holdings in Stryker were worth $5,716,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Capital A Wealth Management LLC bought a new stake in shares of Stryker in the 4th quarter valued at $26,000. Goodman Advisory Group LLC acquired a new position in shares of Stryker during the first quarter worth approximately $32,000. City Holding Co. raised its position in shares of Stryker by 528.6% during the first quarter. City Holding Co. now owns 88 shares of the medical technology company's stock worth $33,000 after purchasing an additional 74 shares during the period. Ransom Advisory Ltd acquired a new position in shares of Stryker during the first quarter worth approximately $37,000. Finally, Smallwood Wealth Investment Management LLC acquired a new position in shares of Stryker during the first quarter worth approximately $40,000. Institutional investors own 77.09% of the company's stock.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the transaction, the director owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This represents a 5.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Viju Menon sold 500 shares of the stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the transaction, the insider owned 12,511 shares of the company's stock, valued at $4,886,921.71. The trade was a 3.84% decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by corporate insiders.

Stryker Stock Performance

NYSE:SYK traded down $5.47 during trading on Friday, reaching $383.32. The company's stock had a trading volume of 985,297 shares, compared to its average volume of 978,978. The firm has a market cap of $146.55 billion, a price-to-earnings ratio of 50.77, a price-to-earnings-growth ratio of 2.80 and a beta of 0.93. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The firm has a 50 day moving average of $388.98 and a 200-day moving average of $379.57. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.07 by $0.06. The firm had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business's revenue for the quarter was up 11.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Research analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a dividend of $0.84 per share. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker's dividend payout ratio is presently 44.50%.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Wall Street Zen raised Stryker from a "hold" rating to a "buy" rating in a research report on Friday, July 18th. Citigroup reaffirmed a "buy" rating and set a $455.00 target price (up from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. BTIG Research reaffirmed a "buy" rating on shares of Stryker in a research report on Monday, July 14th. Truist Financial set a $415.00 price target on Stryker and gave the company a "hold" rating in a research report on Monday, August 4th. Finally, Evercore ISI increased their price target on Stryker from $390.00 to $415.00 and gave the company an "outperform" rating in a research report on Tuesday, July 8th. Fourteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, Stryker currently has an average rating of "Moderate Buy" and a consensus price target of $431.42.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.